Inventor

RENAULD JEAN-CHRISTOPHE

BE34 patents

⚠️ This page may combine multiple inventors who share the name “RENAULD JEAN-CHRISTOPHE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

RENAULD JEAN-CHRISTOPHE

LUDWIG INST CANCER RES

Antibodies which specifically bind T Cell inducible factors (TIFs)

Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors

Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses therefor

Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals

Isolated, tyrosinase derived peptides and uses thereof

Method for inhibiting production of IgE by using IL-9 inhibitors

Method for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereof

Method for modulating cell apoptosis

Isolated cytokine receptor LICR-2

Isolated nucleic acid molecules encoding T cell derived inducible factors

Method of treatment with IL-9 conjugate

Method for treating cell mediated autoimmune disorders using interleukin-9

Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof

Method for diagnosing a disorder characterized by expression of a BAGE tumor rejection antigen precursor

Methods for producing antibodies which specifically bind to interleukin-9 receptor

Isolated tyrosinase derived peptides and uses thereof

Nucleic acid sequences coding for or complementary to nucleic acid sequences coding for interleukin 9 receptor

Method for treating subjects by using BAGE tumor rejection antigen precursors or tumor rejection antigens

Isolated nucleic acid molecule encoding peptides which form complexes with MHC molecules HLA-Cw*1601 and uses thereof

Methods for determining complexes of tumor rejection antigens and HLA-Cw*160/molecules

Isolated nucleic acid molecule encoding peptides which form complexes with MHC molecule HLA-Cw*1601 and uses thereof

Methods for treating interstitial lung disease by using interleukin-9 and its antagonists

LUDWIG INST FOR CANCER RES LTD

Method for inhibiting the immune suppressive function of human T regulatory cells by administering an anti-GARP monoclonal antibody

Anti-GARP protein

Antibody against a complex between human GARP and latent TGF-β

WYETH CORP

Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof

Isolated soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof

Method for identifying a substance which mediates interaction between interleukin 22 and an interleukin 22 receptor

LUDWIG INSTITUE FOR CANCER RES

Isolated nucleic acid molecules which encode T cell inducible factors (TIFS), the proteins encoded, and uses thereof

MEDIMMUNE INC

Recombinant anti-interleukin-9 antibodies

WYETH LLC

Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof

LUDWIG INSTITIUTE FOR CANCER R

Method for making cytokine specific antibodies and uses thereof

RENAULD JEAN-CHRISTOPHE

Method for producing antibody using “naked” expression vector expressing type II transmembrane fusion protein

DELPHI GENETICS SA

Method for producing antibody using “naked” expression vector expressing type II transmembrane fusion protein